Literature DB >> 19446740

DNA repair gene XRCC1 polymorphisms and non-Hodgkin lymphoma risk in a Chinese population.

Jie Liu1, Bao Song, Zhehai Wang, Xianrang Song, Yan Shi, Jingsong Zheng, Jinxiang Han.   

Abstract

Genetic polymorphism in DNA repair genes may influence individual variation in DNA repair capacity, which may be associated with cancer risks. This hospital-based case-control study examined whether polymorphism in the DNA repair gene x-ray repair cross-complementing groups 1 (XRCC1 Arg194Trp [C-->T], Arg280His [G-->A], and Arg399Gln [G-->A]) played a role in susceptibility to non-Hodgkin's lymphoma (NHL) in the Chinese population. We genotyped these polymorphisms for 221 histopathologically confirmed NHL cases and 254 age- and sex-matched healthy control cases in China. No studied polymorphism alone was shown to be related to the risk of NHL or each histologic subtype of NHL. When stratified by smoking status, however, the XRCC1Arg399Gln variant genotypes (homozygotes and heterozygotes) were associated with a 3.0-fold risk of follicular lymphoma among heavy smokers (95% confidence interval: 1.16-7.82; P = 0.02). Further large-scale studies would confirm this association and clarify marginally significant trends in XRCC1 polymorphism combinations for an increased risk for NHL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19446740     DOI: 10.1016/j.cancergencyto.2009.01.015

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  11 in total

1.  The Arg194Trp polymorphism in the XRCC1 gene and cancer risk in Chinese Mainland population: a meta-analysis.

Authors:  Jin Huang; Jie Zhang; Yuliang Zhao; Banghua Liao; Jiaming Liu; Ling Li; Mingheng Liao; Lanlan Wang
Journal:  Mol Biol Rep       Date:  2011-04-16       Impact factor: 2.316

2.  Association between the XRCC1 Arg194Trp polymorphism and risk of cancer: evidence from 201 case-control studies.

Authors:  Yan-Zhong Feng; Yi-Ling Liu; Xiao-Feng He; Wu Wei; Xu-Liang Shen; Dao-Lin Xie
Journal:  Tumour Biol       Date:  2014-07-27

3.  Study on the association between the Arg194Trp polymorphism in the XRCC1 gene and the risk of hematological malignancies.

Authors:  Lizhi Tang; Tianyuan Xiong; Qingyi Jia; Qing He; Xiang Tong; Yuanling Peng; Jiani Shen; Jiqiao Yang; Yonggang Zhang
Journal:  Tumour Biol       Date:  2014-01-12

Review 4.  Impact of DNA polymorphisms in key DNA base excision repair proteins on cancer risk.

Authors:  B Karahalil; V A Bohr; D M Wilson
Journal:  Hum Exp Toxicol       Date:  2012-09-27       Impact factor: 2.903

5.  DNA repair gene polymorphisms in B cell non-Hodgkin's lymphoma.

Authors:  Aykut Bahceci; Semra Paydas; Kahraman Tanriverdi; Melek Ergin; Gulsah Seydaoglu; Gulsum Ucar
Journal:  Tumour Biol       Date:  2014-11-18

6.  Methodology for single nucleotide polymorphism selection in promoter regions for clinical use. An example of its applicability.

Authors:  Herlander Marques; José Freitas; Rui Medeiros; Adhemar Longatto-Filho
Journal:  Int J Mol Epidemiol Genet       Date:  2016-09-30

7.  The Arg399Gln polymorphism in the XRCC1 gene is associated with increased risk of hematological malignancies.

Authors:  Liang Du; Yuqi Liu; Pei Xue; Chenxi Song; Jiani Shen; Qing He; Yuanling Peng; Xiang Tong; Lizhi Tang; Yonggang Zhang
Journal:  Tumour Biol       Date:  2015-01-27

8.  The association between the Arg280His polymorphism in the XRCC1 gene and the risk of hematological malignancies.

Authors:  Xiang Tong; Jiqiao Yang; Yuanling Peng; Jiani Shen; Tianyuan Xiong; Yonggang Zhang; Hong Fan
Journal:  Tumour Biol       Date:  2013-10-06

9.  Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia.

Authors:  Hana Salimizand; Sabrieh Amini; Mohammad Abdi; Bayazid Ghaderi; Namam-Ali Azadi
Journal:  Tumour Biol       Date:  2015-08-07

10.  Genetic variation in DNA repair pathways and risk of non-Hodgkin's lymphoma.

Authors:  Justin Rendleman; Yevgeniy Antipin; Boris Reva; Christina Adaniel; Jennifer A Przybylo; Ana Dutra-Clarke; Nichole Hansen; Adriana Heguy; Kety Huberman; Laetitia Borsu; Ora Paltiel; Dina Ben-Yehuda; Jennifer R Brown; Arnold S Freedman; Chris Sander; Andrew Zelenetz; Robert J Klein; Yongzhao Shao; Mortimer Lacher; Joseph Vijai; Kenneth Offit; Tomas Kirchhoff
Journal:  PLoS One       Date:  2014-07-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.